Now more than ever, market priorities are shaping the core activities of pharmaceutical firms, device companies, health technology assessors, policymakers, and researchers. As drug prices continue to climb and novel therapies challenge traditional pricing models, we are seeing increased momentum behind value-based care and value-based reimbursement. In this white paper, Harvard Medical Professor Anupam Bapu Jena, MD, PhD and Scientific Advisor, Precision Xtract, discusses the key drivers of the value conversation and explores how the definition of value goes beyond quality and cost of care to include other dimensions that should be factored into developing value frameworks.